Brief: Everest Medicines Ltd Entered Into A Collaboration And License Agreement With Kezar Life Sciences
21/09/2023 01:11
Sept 21 (Reuters) - Everest Medicines Ltd 1952.HK :
* ENTERED INTO A COLLABORATION AND LICENSE AGREEMENT WITH
KEZAR
LIFE SCIENCES
* UNDER AGREEMENT, KEZAR GRANTED CO EXCLUSIVE LICENSE TO
DEVELOP,
MANUFACTURE & COMMERCIALIZE KEZAR'S DRUG CANDIDATE ZETOMIPZOMIB
* LICENSE FEE COMPRISES AN UPFRONT PAYMENT OF US$7 MILLION
AND
POTENTIAL CLINICAL, COMMERCIAL MILESTONE PAYMENTS OF UP TO
US$125.5 MILLION
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region